1\. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA
1. Compare serum adropin levels between Obese patients with and without OSA. 2. Correlate serum adropin with OSA severity indices including the Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) and cardiovascular complications. 3. Assess the relationship between serum adropin and endothelial dysfunction markers (endothelin-1). 4. Evaluate adropin's predictive ability for endothelial impairment among OSA patients.
1- Adults aged 20-75 years. 2-obese Patients diagnosed with obstructive sleep apnea (OSA) confirmed by polysomnography.
1-Pregnant females 2-Thyroid disorders 3-Autoimmune diseases 4-chronic liver disease 5-chronic kidney disease 6-drugs as statin,glucocorticoids and antidepressant
The study will include adult obese participants who are referred to the Sleep Medicine/Chest outpatient clinic with suspected obstructive sleep apnea. Participants will undergo clinical assessment and overnight polysomnography (PSG) to confirm the diagnosis of OSA and determine its severity according to the apnea-hypopnea index (AHI). Participants will be categorized into appropriate study groups according to the presence and severity of OSA. A suitable comparison group of obese participants without OSA may also be included, according to the study design. The study population will include both males and females who meet the predefined inclusion criteria and provide informed consent to participate in the study
Case-control
Retrospective
Adropin
Diagnostic testFasting blood samples of Adropin were obtained by venipuncture in the morning following the sleep study.
Serum adropin levels (measured by ELISA)
* Serum adropin levels (measured by ELISA) * Association between serum adropin and endothelial function (Endothelin -1).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
